United States was Recursion Pharmaceuticals’s largest region in fiscal 2025, bringing in $39.34M of $74.68M (53%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| United States | $43.81M | $57.38M | $39.34M |
| United Kingdom | — | $1.14M | $35.34M |
| Other | $769.00K | $327.00K | — |
| Total | $44.58M | $58.84M | $74.68M |
Recursion Pharmaceuticals brought in $74.68M from its two regions in fiscal 2025, the year ended December 31, 2025. Recursion Pharmaceuticals regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $58.84M. United States was the largest at $39.34M (52.7%), ahead of United Kingdom at $35.34M (47.3%).
Compared with fiscal 2024, United Kingdom grew 3,013.4% to $35.34M, while United States fell 31.4% to $39.34M.
Recursion Pharmaceuticals began breaking out United Kingdom in fiscal 2024, when it brought in $1.14M. Recursion Pharmaceuticals stopped reporting Other as a separate region after fiscal 2024, when it brought in $327.00K.
Operating Revenue was Recursion Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $74.26M of $74.68M (99%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Operating Revenue | $39.68M | $43.88M | $58.49M | $74.26M | |||
| Grant Revenue | $162.00K | $699.00K | $351.00K | $425.00K | |||
| Total | $39.84M | $44.58M | $58.84M | $74.68M |
Recursion Pharmaceuticals brought in $74.68M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 26.9% from $58.84M in fiscal 2024. Operating Revenue was the largest at $74.26M (99.4%), ahead of Grant Revenue at $425.00K (0.6%).
From fiscal 2022 to 2025, combined revenue from these lines grew from $39.84M to $74.68M, a compound annual growth rate of 23.3%. Operating Revenue's share held steady at about 99.4%.
Recursion Pharmaceuticals (RXRX) reports its revenue by geography and by product and service. In fiscal 2025, United States was its largest region, bringing in $39.34M (52.7% of the total), followed by United Kingdom at $35.34M (47.3%).
United States was Recursion Pharmaceuticals' largest region in fiscal 2025, bringing in $39.34M, or 52.7% of the $74.68M total across its two regions.
Operating Revenue was Recursion Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $74.26M, or 99.4% of the $74.68M total across its two product and service lines.
Every figure comes from Recursion Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Recursion Pharmaceuticals gives it, and years follow its fiscal calendar.
Recursion Pharmaceuticals' revenue by geography goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.